SG
PRAX icon

StoneX Group’s Praxis Precision Medicines PRAX Stock Holding History

StoneX Group’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$508K Buy
1,521
+52
+4% +$16.5K 0.02% 561
2026
Q1 		$473K Sell
1,469
-297
-17% -$91.9K 0.03% 439
2025
Q4 		$521K Buy
+1,766
New +$329K 0.02% 523

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

StoneX Group's PRAX Position: Q2 2026 in Review

StoneX Group increased its Praxis Precision Medicines (PRAX) stake by 3.5% in Q2 2026, buying an estimated $16.5K and bringing the position to 1,521 shares worth $508K. The position accounts for 0.02% of the portfolio, ranked #561.

StoneX Group first reported a position in PRAX in Q4 2025 and has held it in 3 quarters since. The position peaked at $521K in Q4 2025. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • StoneX Group held 1,521 shares of Praxis Precision Medicines worth $508K as of Q2 2026.
  • StoneX Group bought 52 Praxis Precision Medicines shares in Q2 2026, an estimated $16.5K.
  • Praxis Precision Medicines made up 0.02% of StoneX Group's portfolio in Q2 2026, its #561 holding.
  • StoneX Group first reported a position in Praxis Precision Medicines in Q4 2025 and has held it in 3 quarters since.
  • StoneX Group's Praxis Precision Medicines position peaked at $521K in Q4 2025.
  • 310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.